Why Vertex Pharmaceuticals Incorporated (VRTX) stock moved
Updated Sep 27, 2026
Vertex Pharmaceuticals Incorporated (VRTX) shares rose 0.7% to $526.19 as of September 27, 2026, a slight gain from the prior close of $522.38. BestStocks flagged the session as a major change for VRTX. The move is tied to price move down. Below, we break down what changed for VRTX, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
VRTX climbed 0.7% to $526.19
VRTX rose 0.7% in its latest session, moving from $522.38 to $526.19.
Material / EarningsSector-Wide MoveLow confidence
Rel. volume
0.5×
Below Avg
Vs peers
Top 2 of 7 peers
Outperforming
Market cap
$133.5B
NASDAQ Global Select
Analyst target
$571
+8.5% vs price
Price chart
Aug 27 – Sep 25
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Vertex Pharmaceuticals Incorporated investors
For Vertex Pharmaceuticals Incorporated investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Positive 0.7% session move. Weighing against that: VRTX moved -4.56% from $522.25 to $498.43 on 2026-07-08; New SEC filing — review for material disclosures. Because peers moved similarly, the shift looks more macro- or sector-driven than a change in VRTX's fundamentals. Wall Street's consensus price target sits at $570.93, implying +8.5% upside from $526.19. BestStocks rates the overall signal quality low (43/100). With earnings roughly 36 days out, the next report is the most likely near-term test of the move.
VRTX price reaction
VRTX last traded at $526.19, up $3.81 (+0.73%) from the previous close of $522.38. The session traded on 0.5× average volume (below avg), so participation was unremarkable. Its healthcare peer group moved a median +0.2% over the same stretch, leaving VRTX ahead of the group by 0.5 points. Over the past month the stock has ranged between $508.34 and $557.96, and it currently sits about 36% of the way up that band.
Bullish and bearish analyst opinions on Vertex Pharmaceuticals Incorporated (VRTX)
The consensus analyst price target on Vertex Pharmaceuticals Incorporated (VRTX) is $570.93, 8.5% above the recent $526.19. Over the past 90 days analysts logged 0 upgrades, 9 maintains, and 0 downgrades. Here is how the bullish and bearish cases on VRTX line up.
▲ The bullish case
+Wall Street's consensus price target of $570.93 implies +8.5% upside from $526.19.
+The Street's most bullish target is $665.00 (+26.4%).
+Material positive event.
+Positive 0.7% session move.
+Positive price momentum.
▼ The bearish case
−The most bearish analyst target is $350.00 (-33.5%).
−VRTX moved -4.56% from $522.25 to $498.43 on 2026-07-08.
−Vertex Pharmaceuticals Incorporated (VRTX) moved -2.89% from $539.50 to $523.91 on 2026-08-10.
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 27, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Vertex Pharmaceuticals Incorporated (VRTX) moved -0.11% from $513.80 to $513.26 on 2026-09-16. We checked news, earnings, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move appears to be part of a modest sector decline (UNH -2.16%), with VRTX hitting a new 30-day low on below-average volume.
Material / Earnings2026-09-03+0.2%
Vertex Pharmaceuticals Incorporated (VRTX) moved -0.19% from $559.00 to $557.96 on 2026-09-03. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The stock reached a new 30-day high at $557.96 on below-average volume (0.7x the 5-day mean).
Vertex Pharmaceuticals completed its $10.0 billion acquisition of Crinetics Pharmaceuticals at $85.00 per share in cash, expanding its executive leadership team and establishing endocrinology as its fifth major therapeutic pillar alongside cystic fibrosis, hematology, acute pain, and renal disease. VRTX rose +1.03% to $553.28 on elevated volume of 383,166 shares (2.11x time-adjusted average), reflecting positive investor reception of the finalized deal.
News2026-08-20-2.1%
Vertex's potential competitor suffered a clinical setback, removing near-term competitive threat to core business.
Material / Earnings2026-08-19+4.5%
Vertex Pharmaceuticals Incorporated (VRTX) moved +2.71% from $537.47 to $552.06 on 2026-08-19. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move appears to be part of a sector-wide rally: seven pharma peers including Amgen (+5.48%), Merck (+11.95%), AbbVie (+6.25%), and Pfizer (+5.10%) moved in the same direction on the same day.
Vertex Pharmaceuticals gained 3.32% to $532.68, extending momentum from its recent second-quarter earnings and raised 2026 revenue guidance of $13.1–$13.2 billion (per web synthesis corroborated by Yahoo Finance sources). The rally also reflects competitive advantage after a rival cystic fibrosis clinical trial setback. Volume of 500K shares ran at 0.82x the historical average, consistent with normal intraday rhythm at this point in the session.
Vertex Pharmaceuticals rallied 8.87% to $540.08 following strong Q2 2026 earnings and raised full-year guidance. The company reported 12% revenue growth to $3.33 billion in the quarter and lifted 2026 revenue guidance to $13.1–$13.2 billion, driven by strength in its cystic fibrosis franchise and newer products CASGEVY and JOURNAVX (finance.yahoo.com). Major Wall Street firms including RBC, UBS, Barclays, and Goldman Sachs reiterated bullish ratings or raised price targets in response.
Activity2026-08-10+5.6%
Vertex Pharmaceuticals Incorporated (VRTX) moved -2.89% from $539.50 to $523.91 on 2026-08-10. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. Volume was 1.9x the 5-day average, and the stock reached a new 30-day high, suggesting technical positioning rather than fundamental news drove the move.
Upcoming catalysts & outlook
Next earnings
2026-11-02 (est.)
in 36 days
10-Q Filing (est.)
2026-11-03
Medium impact
Thesis shift
Neutral / Mixed
bullish signal
Risk level
Medium
from change events
Frequently asked questions about VRTX
Why did Vertex Pharmaceuticals Incorporated (VRTX) stock move?
VRTX rose 0.7% to $526.19. No single company-specific catalyst was confirmed during the move window, and it looks like a sector-wide move.
How much did VRTX stock rise?
VRTX gained 0.73% ($3.81) versus the prior close of $522.38, last trading at $526.19 on 0.5× average volume.
When is Vertex Pharmaceuticals Incorporated's next earnings date?
VRTX's next earnings report is estimated for 2026-11-02 — about 36 days away.
What is the analyst price target for VRTX?
The consensus analyst price target for VRTX is $570.93, about 8.5% above the current $526.19. Over the past 90 days, analysts recorded 0 upgrades, 9 maintains, and 0 downgrades.
Is the VRTX move company-specific or sector-wide?
BestStocks classifies it as a sector-wide move: the peer group moved a median +0.2% against VRTX's +0.7%. VRTX ranks top 2 of 7 peers.
How BestStocks tracks VRTX
This page is generated automatically by BestStocks' change-detection system after price move down was detected and verified against independent data sources. It draws on 20 tracked change events for VRTX, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 27, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
